Latest Conference

Mike Kohut, PhD shares the results of his research that reveals providers are writing prescriptions for infections based largely on patient demand and not guideline recommendations.

Previously seen in Wisconsin in 2015-2016, Elizabethkingia seems to have made its way to the Empire state.

Emil Lesho, DO, FACP, FIDSA, FSHEA, explains what makes Elizabethkingia unique.

A recent survey explores prevention practices for Legionnaires’ disease and water management programs in health care facilities.

Dr. Thomas Sandora shares recent data on screening for asymptomatic carriage of Clostridium difficile and provides insight into what the preferred first-line treatment for the infection in children.

Contagion® Editorial Advisory Board member, James S. Lewis, PharmD, FIDSA, shares how antibiotic stewards can craft stewardship interventions to their own reality.

Kari Simonsen, MD, and Matthew Linam, MD debate the best way to measure and improve hand hygiene compliance.

In the SHEA Spring 2018 Opening Plenary, Zintars Beldavs stresses the importance of communication and collaboration in the fight against antimicrobial resistance.

Researchers compare CLABSIs attributed to CRE in short-term acute care hospitals with long-term acute care hospitals using data reported to NHSN in 2015-2016.

PIV infections are not as rigorously studied as CLABSIs, but they should be.

Contagion® will be covering the conference, and so, keep a look out for session coverage as well as interviews with some of the key presenters.

The FDA grants Fast Track designation to TAK-426, Takeda’s purified, inactivated, alum-adjuvanted whole Zika virus vaccine candidate.

Daniel Diekema, MD, explains how clinicians can actively work to prevent pathogen spread in their health care facilities.

Pedro Cahn, MD, describes the risk associated with raltegravir HD.

Michael Edmond, MD, MPH, MPA, stresses that a collaborative effort is needed to control C. difficile in hospitals.

Pedro Cahn, MD, explains who the target population is for raltegravir HD.

Daniel Diekema, MD, describes recent developments made in rapid and molecular diagnostic testing in the microbiology lab, and how these tests strengthen infection prevention efforts.

Michael Edmond, MD, MPH, MPA, explains who is in charge of leading infection control programs in hospitals.

Pedro Cahn, MD, shares the results found after 96-weeks of follow-up for the onceMRK Phase 3 clinical trial.

Jake Glaser describes how recent advances against HIV & AIDS have affected the philanthropic community.

Jake Glaser explains the challenges faced when fundraising for AIDS programs in the 21st century.

Michael Edmond, MD, MPH, MPA, explains how strategies are developed to address different threats in health care settings.

Jake Glaser shares who he feels is going to end the AIDS epidemic.

Jake Glaser shares what is needed to achieve the Fast-Track strategy to end the AIDS epidemic by 2030.

Daniel Diekema, MD, discusses the different roles that clinical laboratories play in outbreak response.

Michael Edmond, MD, MPH, MPA, explains how health care facilities can work on preparing for the unexpected in the realm of infectious diseases.

Daniel Diekema, MD, explains why microbiology labs should be seen as an integral part of antimicrobial stewardship efforts.

A testing stewardship effort found that using a “hard stop” alert system may help reduce inappropriate C. difficile testing.

James S. Lewis, PharmD, FIDSA, explains how pharmacists can advocate for judicious antibiotic use in patients through educating the patients themselves, as well as providers.

Daniel Diekema, MD, explains how the microbiology lab works to provide optimal drug selection for empiric and directed therapy.